TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04318015

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: All placebo will be administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: All placebo will be administered orally
Study: NCT03222843

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo
Description: once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo
Description: once daily
Study: NCT01902446

Intervention type: DRUG
Intervention: Chlorhexidine gluconate
Description: Study solution will be applied to the oropharynx and will be distributed for 15 seconds with a swab stick. No suction will be applied for at least 30 seconds.
Study: NCT00902564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Flexible-dosed (5 to 20 mg Oral Tablets Daily)
Study: NCT00588445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Patients will receive gefitinib 250 mg po daily for at least 21 days preoperatively (depending on the timing of the surgery). Treatment with gefitinib will be stopped 2 days before the date of surgery.~Patients who have had at least a minor response to gefitinib therapy preoperatively (\> 25% reduction in tumor measured bidimensionally) and / or have mutations in the protein-tyrosine kinase domain of the EGF receptor gene identified will continue on the study and will resume gefitinib treatment after at least 7 days from surgery providing adequate wound healing has occurred.~Patients who are determined to be candidates for adjuvant chemotherapy and/or radiation therapy by their treating physician may receive treatment with adjuvant chemotherapy and/or radiation therapy. The post-operative gefitinib will be started after completion of the chemotherapy and/or radiation therapy.
Study: NCT04255004

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pall Celeris System, point of care device for human cell therapy
Description: Concentration of PB-MNCs autologous cell therapy was produced by a filtration-based point-of-care device. All the procedures were performed in operatory room with anaesthesiologic support (propofol and/or peripheral block). Blood withdrawal (120 ml) was collected through a peripheral venous access. Blood was loaded, and gravity filtration was allowed to proceed until the upstream side of the filter had no remaining blood; filtration last about 10 minutes. During filtration, MNCs were captured in the filter while plasma, platelets (PLTs) and red blood cells (RBCs) were not retained. Immediately concentrate solution is injected in the perilesional area and intramuscular in the foot and the leg (0.2-0.3cc in boluses) below the knee, at intervals of 1-2 cm and to a mean depth of 1.5-2 cm, using a 21G needle. This procedure is repeated on each patient for three times, at intervals of 30-45 days from each other.
Study: NCT02788708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Mesylate
Description: Given PO
Study: NCT00579059

Intervention type: DEVICE
Group type: OTHER
Intervention: Maxim® Knee System with Removable Molded Polyethylene Tibia
Description: Used for total knee replacements

Intervention type: DEVICE
Group type: OTHER
Intervention: Regular Maxim® Knee System
Description: Used for total knee replacements
Study: NCT03092076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: 180 mg loading dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: 180 mg loading dose
Study: NCT02452320

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous acetaminophen
Description: administration of 1000mg of intravenous acetaminophen or placebo every 6 hours for a total of 4 doses; first dose to be administered after induction of general anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to placebo will receive every 6 hours for a total of 4 doses; first dose to be administered after induction of general anesthesia
Study: NCT00310440

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: P-15 Synthetic osteoconductive bone substitute
Description: Safety and efficacy of synthetic bone substitute used for fusion in spinal surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autologous bone
Description: Local autologous bone will be harvested, milled and placed into the cavity of the structural allograft ring
Study: NCT02185638

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Appetite suppressant properties of YGD and A20-50
Description: 3-arm crossover study for investigation of the effect of herbal supplements A20-50 compared to YGD blend and placebo on subjective appetite sensations, glucose, insulin, ghrelin, GLP-1, CCK and ad libitum energy intake

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Appetite suppressant properties of YGD and A20-50
Description: 3-arm crossover study for investigation of the effect of herbal supplements A20-50 compared to YGD blend and placebo on subjective appetite sensations, glucose, insulin, ghrelin, GLP-1, CCK and ad libitum energy intake

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Appetite suppressant properties of YGD and A20-50
Description: 3-arm crossover study for investigation of the effect of herbal supplements A20-50 compared to YGD blend and placebo on subjective appetite sensations, glucose, insulin, ghrelin, GLP-1, CCK and ad libitum energy intake
Study: NCT01251666

Intervention type: OTHER
Group type: OTHER
Intervention: Colonoscopy
Description: Colonoscopy if at least one of the faecal occult blood tests is positive (blinded to each test result)
Study: NCT03898882

Intervention type: DRUG
Intervention: oxytocin
Description: PK measurements of oxytocin

Intervention type: DRUG
Intervention: oxytocin
Description: PK measurements of oxytocin

Intervention type: DEVICE
Intervention: Shore durometer
Description: The investigators will take serial readings from a digital durometer at the uterine fundus at 3, 6, 9 and 12 minutes following OXT administration to provide data that will inform an estimate of the timing of peak effect. Shore durometers measure the hardness of materials on a scale of 0-100 Shore Units (SU). Preliminary (unpublished) data provided a range of 10-56 SU after oxytocin administration at cesarean delivery. Durometer readings were also shown to correlate positively with the obstetrician's manual assessment of uterine contractility, which is traditionally used to determine the success or failure of uterotonic therapy.

Intervention type: DEVICE
Intervention: Shore durometer
Description: The investigators will take serial readings from a digital durometer at the uterine fundus at 3, 6, 9 and 12 minutes following OXT administration to provide data that will inform an estimate of the timing of peak effect. Shore durometers measure the hardness of materials on a scale of 0-100 Shore Units (SU). Preliminary (unpublished) data provided a range of 10-56 SU after oxytocin administration at cesarean delivery. Durometer readings were also shown to correlate positively with the obstetrician's manual assessment of uterine contractility, which is traditionally used to determine the success or failure of uterotonic therapy.
Study: NCT02643420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPI-2012
Description: Single-use syringes for subcutaneous injection, administered on Day 2 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Single-dose subcutaneous injection administered on Day 2 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Standard therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Standard therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Standard therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Standard therapy
Study: NCT01928186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorothymidine F-18
Description: Undergo FLT PET
Study: NCT04551950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: Participants received bintrafusp alfa until confirmed disease progression, death, unacceptable toxicity and study withdrawal maximum of 2 years (at the discretion of the Investigator).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: Participants received bintrafusp alfa until confirmed disease progression, death, unacceptable toxicity and study withdrawal maximum of 2 years (at the discretion of the Investigator).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: Participants received bintrafusp alfa until confirmed disease progression, death, unacceptable toxicity and study withdrawal maximum of 2 years (at the discretion of the Investigator).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin was administered intravenously as per standard of care.
Study: NCT03532152

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pure Purr VR technology
Description: The Pure Purr technology consists of BoboVR X1 headset with pre-installed software. The virtual reality headset reproduces a dynamic video content that is visually perceived with the help of the high-resolution screen. Also, the headset is able to play audio and transmit it via the headphones.~The audio sequence has been modified by adding a binaural effect and has been synchronized with the tact of respiratory movements and the frequency of heart rate.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham VR technology
Description: The sham technology includes an identical BoboVR X1 virtual reality headset with pre-installed software. The audio-visual sequence is similar to the one in the investigational version of the software. The key difference is that the audio sequence has not been modified with the binaural effect and has not been synchronized with the tact of respiratory movements and the frequency of heart rate.
Study: NCT04551950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin was administered intravenously as per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel was administered intravenously as per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel was administered intravenously as per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab was administrated as indicated for standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin was administered intravenously as per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin was administered intravenously as per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin was administered intravenously as per standard of care.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Participants received radiotherapy as per standard of care.
Study: NCT01802190

Intervention type: GENETIC
Intervention: Deafness patients
Description: SLC17A8 et POU4F3 mutations genes analysis on blood samples of deafness patients.
Study: NCT02106520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02657447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betalutin with lilotomab dose 1
Description: 15 MBq/kg b.w. Betalutin (lutetium (177Lu) lilotomab satetraxetan) single injection, with lilotomab pre-dosing, dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betalutin with lilotomab dose 2
Description: 15 MBq/kg b.w. Betalutin (lutetium (177Lu) lilotomab satetraxetan) single injection, with lilotomab pre-dosing, dose 2
Study: NCT01928186

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FLT PET
Study: NCT04161261

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation
Description: To measure the facial nerve stimulation threshold for one mid-array and one apical electrode of the implant using the pulse-train stimuli

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation
Description: To measure the facial nerve stimulation threshold for one mid-array and one apical electrode of the implant using the pulse-train stimuli
Study: NCT01928186

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Run-in (short pre-surgery course) of endocrine-targeted therapy
Description: Patients undergo run-in (short pre-surgery course) of endocrine-targeted therapy with aromatase inhibitor between the two (baseline and repeat) FLT PET scans. This is not an experimental therapy. This is a standard of care therapy that patients will continue after surgery, when the study is completed.
Study: NCT04077112

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Child Interaction Therapy
Description: Behavioral parent training program targeting parent-child relationship

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent Child Interaction Therapy
Description: Behavioral parent training program targeting parent-child relationship
Study: NCT03879811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMZ
Description: Oral TMZ at 150mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab via IV infusion at 480 mg every four weeks (Q4W) starting 4 weeks after TMZ day 1
Study: NCT00066027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg doxycycline hyclate
Description: Subjects in the LDD group took 20 mg doxycycline hyclate tablets twice daily for two years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in the placebo group took a placebo look-alike twice daily for two years.
Study: NCT02296255

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix®, GlaxoSmithKline
Description: 3 doses (0,1,6 months) of Cervarix®, GlaxoSmithKline
Study: NCT02396589

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education Group
Description: Attention will be provided to the control group to ensure they experience the same effects of time and attention but no effect on the outcome of interest.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Modifications Group
Description: The standardized components include assessment, identification of five problematic activities (and environmental barriers), identification of three solutions (for each problem), implementation of a solution set selected by the participant, training, and active practice of daily activities in one's own home and community.
Study: NCT05848427

Intervention type: OTHER
Intervention: LUSZ P
Description: LUSZ protocol applied to WOSS in-hospitalized Covid-19 patients: a Corticosteroid Therapy-enhanced Standard Care (CTSC), a standard care enhanced by corticosteroid (methylprednisolone) treatment.

Intervention type: OTHER
Intervention: LUSZ P
Description: LUSZ protocol applied to WOSS in-hospitalized Covid-19 patients: a Corticosteroid Therapy-enhanced Standard Care (CTSC), a standard care enhanced by corticosteroid (methylprednisolone) treatment.

Intervention type: OTHER
Intervention: LUSZ P
Description: LUSZ protocol applied to WOSS in-hospitalized Covid-19 patients: a Corticosteroid Therapy-enhanced Standard Care (CTSC), a standard care enhanced by corticosteroid (methylprednisolone) treatment.

Intervention type: OTHER
Intervention: LUSZ P
Description: LUSZ protocol applied to WOSS in-hospitalized Covid-19 patients: a Corticosteroid Therapy-enhanced Standard Care (CTSC), a standard care enhanced by corticosteroid (methylprednisolone) treatment.
Study: NCT00407303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obatoclax mesylate
Description: 30 mg, 45 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obatoclax mesylate
Description: 30 mg, 45 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obatoclax mesylate
Description: 30 mg, 45 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.0mg/m2, 1.3 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.0mg/m2, 1.3 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.0mg/m2, 1.3 mg/m2
Study: NCT04117282

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: gait training
Description: training for improving the quality of gait through adjusting gait cycle phases time and improving the functional level and independence during gait

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gait training
Description: training for improving the quality of gait through adjusting gait cycle phases time and improving the functional level and independence during gait
Study: NCT00808665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patients will be given 0.7 mcg/kg/hr of dexmedetomidine over the first hour of surgery, followed by continuous infusion of 0.5 mcg/kg/hr of dexmedetomidine for the next 2 hours of surgery. Dexmedetomidine dose will be reduced to 0.2 mcg/kg/hr for the duration of the procedure and continued at that rate for four hours postoperatively. Patients in the placebo arm will receive an equal per-kg IV volume of 0.9% Sodium Chloride over the same periods. Drug administration will be controlled for both arms of the study using a continuous infusion pump.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline
Description: Patients in the placebo arm will receive an equal per-kg IV volume of 0.9% Sodium Chloride over the same periods. Drug administration will be controlled for both arms of the study using a continuous infusion pump.
Study: NCT00715780

Intervention type: DRUG
Intervention: soluble human insulin
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation

Intervention type: DRUG
Intervention: biphasic human insulin
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation

Intervention type: DRUG
Intervention: insulin NPH
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study: NCT00662116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alagebrium
Description: 200 mg (two 100 mg tablets) two times daily for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablets - two tablets taken twice daily
Study: NCT01991119

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propafenone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dronedarone
Study: NCT00715780

Intervention type: DRUG
Intervention: insulin aspart
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation

Intervention type: DRUG
Intervention: biphasic insulin aspart
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation

Intervention type: DRUG
Intervention: insulin detemir
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study: NCT02138929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Induction and Dose Expansion Phase: 10 mg by mouth daily in a 28 day cycle.
Study: NCT03579810

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigational
Description: The educational intervention helped to increase the knowledge of attitudes, and habits of healthy lifestyle in children, parents and teachers and it was based on health promotion models and social cognitive theory, to be articulated with the Institutional Educational Project through the pedagogical component that integrates three areas, physical activity, healthy eating, and the knowledge of the body and the heart with the dynamics of the educative community.~The program covered self-care of the body and heart, healthy diet, and physical activity

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control group did not receive an educational intervention in areas of physical activity, healthy eating, and the knowledge of the body and the heart. Instead, children received the standard curriculum in health and physical activity of the national Ministry of Education.
Study: NCT03367143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Study: NCT02983864

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BASICS
Description: A one session intervention focused on reducing drinking with motivational interviewing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Integrated BASICS
Description: A one session intervention focused on reducing drinking and sexual behavior while drinking

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation
Description: A one session intervention focused on increasing relaxation skills

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Integrated Bystander
Description: A one session intervention focused on reducing sexual assault with a focus on the role of alcohol
Study: NCT02112864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 10 mg (2.5 ml)
Study: NCT02138929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE 225
Description: Induction Phase Starting Dose: 400 mg by mouth daily in a 28 day cycle.~Expansion Phase Starting Dose: Maximum tolerated dose from Induction Phase.
Study: NCT04586608

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MCT/ω-3 fatty acids
Description: The provision of ω-3 fatty acids to premature neonates in the Parenteral Nutrition.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: soybean oil-based IVFE
Description: soybean oil-based IVFE